STRATA Skin Sciences, Inc. Aktie News

STRATA Skin Sciences, Inc. ( SSKN ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Dolev Rafaeli - President, CEO & Vice-Chairman John Gillings - Principal Financial Officer & Chief Accounting Officer Conference Call Participants Jules Abraham - CorProminence, LLC Destiny Buch - Ladenburg Thalmann & Co. Inc., Research Division Jeremy Pearlman - Maxim Group LLC, Researc...

Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion

HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close.

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTRAC capability to address the condition

HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTR...

HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a new peer-reviewed study in Lasers in Medical Science that reinforces the Company's commitment t...

Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market growth and expanding indications Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued marke...

HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shar...